skip to main content
Idioma:

Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study

Bandini, M. ; Gibb, E.A. ; Gallina, A. ; Raggi, D. ; Marandino, L. ; Bianchi, M. ; Ross, J.S. ; Colecchia, M. ; Gandaglia, G. ; Fossati, N. ; Pederzoli, F. ; Lucianò, R. ; Colombo, R. ; Salonia, A. ; Briganti, A. ; Montorsi, F. ; Necchi, A.

Annals of oncology, 2020-12, Vol.31 (12), p.1755-1763 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
  • Título:
    Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
  • Autor: Bandini, M. ; Gibb, E.A. ; Gallina, A. ; Raggi, D. ; Marandino, L. ; Bianchi, M. ; Ross, J.S. ; Colecchia, M. ; Gandaglia, G. ; Fossati, N. ; Pederzoli, F. ; Lucianò, R. ; Colombo, R. ; Salonia, A. ; Briganti, A. ; Montorsi, F. ; Necchi, A.
  • Assuntos: Antibodies, Monoclonal, Humanized ; Chemotherapy, Adjuvant ; Cystectomy ; Disease-Free Survival ; event-free survival ; Humans ; muscle-invasive bladder cancer ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local - drug therapy ; pathological response ; pembrolizumab ; radical cystectomy ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - surgery
  • É parte de: Annals of oncology, 2020-12, Vol.31 (12), p.1755-1763
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Initial studies of preoperative checkpoint inhibition before radical cystectomy (RC) have shown promising pathologic complete responses. We aimed to analyze the survival outcomes of patients enrolled in the PURE-01 study (NCT02736266). We report the results of the secondary end points of PURE-01 in the final population of 143 patients. In particular, we report the event-free survival (EFS) outcomes, defined as the time from the first cycle of pembrolizumab to radiographic disease progression precluding RC, initiation of neoadjuvant chemotherapy (NAC), recurrence after RC, or death from any cause. Other end points were recurrence-free survival (RFS) and overall survival (OS). Subgroup analyses were carried out, including pathological response category, clinical complete responses (CR) assessed via multiparametric magnetic resonance imaging (mpMRI), and molecular subtyping. Cox regression analyses for EFS were also carried out. After a median [interquartile range (IQR)] follow-up of 23 (15-29) months, 12- and 24-month EFS were 84.5% [95% confidence interval (CI): 78.5-90.9] and 71.7% (62.7-82). The prognosis was favorable across all the different pathological response subgroups, with the exception of ypN+ (N = 21), showing a 24-month RFS (95% CI) of 39.3% (19.2% to 80.5%). A statistically significant EFS benefit was observed in patients with a clinical CR (P = 0.002). Programmed cell-death-ligand-1 combined positive score was significantly associated with longer EFS in multivariable analyses. Four patients refused RC after clinical evidence of CR, and none of them have recurred after a median follow-up of 10 months (IQR: 11-15). The claudin-low subtype displayed a numerically longer EFS after pembrolizumab and RC compared with the other subtypes. The EFS results from PURE-01 revealed that the immunotherapy effect was maintained post-RC in most patients. Pembrolizumab compared favorably with neoadjuvant chemotherapy, irrespective of the biomarker status. Molecular subtyping may be a useful tool to select the patients who are predicted to benefit the most from neoadjuvant pembrolizumab. •The PURE-01 study tested neoadjuvant pembrolizumab in patients with muscle invasive bladder cancer.•Pembrolizumab has shown promising activity in this setting, reaching 38.5% of complete response (ypT0ypN0).•Event-free survival is also encouraging with 84.5% and 71.7% rates at 12 and 24 months from immunotherapy initiation.•Survival benefit seems spread to all pathological response subgroups with the exception of ypN+ patients.•Molecular subtyping may be a useful tool to select the patients who are predicted to benefit the most from neoadjuvant pembrolizumab.
  • Editor: England: Elsevier Ltd
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  2 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.